氯苯唑酸葡甲胺
Tier B — Position earlyTafamidis Meglumine
Targets：TTR
Brand：维达全、Vyndaqel
Indications (approved)：淀粉样多神经病、转甲状腺素运载蛋白淀粉样变性、淀粉样变
Regional status
Synthetic routes & intermediates6 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| TAFA-001 | 2374-03-0 | 4-amino-3-hydroxybenzoic acid |
| TAFA-002 | 2905-62-6 | 3,5-dichlorobenzoyl chloride |
| TAFA-003 | 1184581-58-5 | 4-(3,5-dichlorobenzamido)-3-hydroxybenzoic acid |
| TAFA-004 | 594839-88-0 | 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid |
| TAFA-005 | 1395964-06-3 | methyl 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylate |
| Code | CAS No. | Intermediate |
|---|---|---|
| TAFA-001 | 2374-03-0 | 4-amino-3-hydroxybenzoic acid |
| TAFA-006 | 154235-77-5 | benzo[d]oxazole-6-carboxylic acid |
| TAFA-007 | 1334429-35-4 | benzo[d]oxazol-6-yl(morpholino)methanone |
| TAFA-008 | 3032-81-3 | 1,3-dichloro-5-iodobenzene |
| TAFA-009 | - | (2-(3,5-dichlorophenyl)benzo[d]oxazol-6-yl)(morpholino)methanone |
| Code | CAS No. | Intermediate |
|---|---|---|
| TAFA-005 | 1395964-06-3 | methyl 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylate |
| TAFA-010 | 1305711-40-3 | methyl benzo[d]oxazole-6-carboxylate |
| TAFA-011 | 1469474-17-6 | (3,5-dichlorophenyl)(mesityl)iodonium trifluoromethanesulfonate |
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)409139-1-a | 51-36-5 | 3,5-Dichlorobenzoic acid |
| (II)409139-1-a | 2905-62-6 | 3,5-Dichloro-1-benzenecarbonyl chloride |
| (IIIa)409139-1-a | 2374-03-0 | (4-Carboxy-2-hydroxyphenyl)amine |
| (IIIb)409139-1-a | 106896-49-5 | 2-Bromo-4-methoxycarbonylaniline |
| (IIIc)409139-1-a | 63435-16-5 | 2-Hydroxy-4-methoxycarbonylaniline |
| (IIId)409139-1-a | 499157-23-2 | 4-Amino-3-hydroxybenzoic acid methyl ester hydrochloride |
| (IVa)409139-1-a | 1184581-58-5 | 4-(3,5-Dichlorobenzamido)-3-hydroxybenzoic acid |
| (IVb)409139-1-a | 2376718-48-6 | Methyl 3-bromo-4-(3,5-dichlorobenzamido)benzoate |
| (IVc)409139-1-a | 2505157-36-6 | Methyl 4-(3,5-dichlorobenzamido)-3-hydroxybenzoate |
| (V)409139-1-a | 1395964-06-3 | 2-(3,5-Dichlorophenyl)benzoxazole-6-carboxylic acid methyl ester |
| (VI)409139-1-a | 1305711-40-3 | Methyl 1,3-benzoxazole-6-carboxylate |
| (VII)409139-1-a | 541-73-1 | 1,3-Bis(chloranyl)benzene |
| (VIII)409139-1-a | 594839-88-0 | 2-(3,5-Dichlorophenyl)benzo[d]oxazole-6-carboxylic acid |
| (IX)409139-1-a | 99-06-9Available | 3-Carboxyphenol |
| (X)409139-1-a | 619-14-7 | 3-Carboxy-6-nitrophenol |
| Code | CAS No. | Intermediate |
|---|---|---|
| (Ia)409139-8-a | 63435-16-5 | 2-Hydroxy-4-methoxycarbonylaniline |
| (Ib)409139-8-a | 183968-79-8 | Butyl 4-amino-3-hydroxybenzoate |
| (Ic)409139-8-a | - | tert-Butyl 4-amino-3-hydroxybenzoate |
| (Id)409139-8-a | 4351-89-7 | Phenyl 4-amino-3-hydroxybenzoate |
| (II)409139-8-a | 10203-08-4Available | 3,5-Dichlorobenzaldehyde |
| (IIIa)409139-8-a | 1395964-06-3 | 2-(3,5-Dichlorophenyl)benzoxazole-6-carboxylic acid methyl ester |
| (IIIb)409139-8-a | - | Butyl 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylate |
| (IIIc)409139-8-a | - | tert-Butyl 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylate |
| (IIId)409139-8-a | - | Phenyl 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylate |
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)409139-10-a | 2374-03-0 | (4-Carboxy-2-hydroxyphenyl)amine |
| (II)409139-10-a | 63435-16-5 | 2-Hydroxy-4-methoxycarbonylaniline |
| (III)409139-10-a | 51-36-5 | 3,5-Dichlorobenzoic acid |
| (IV)409139-10-a | 2505157-36-6 | Methyl 4-(3,5-dichlorobenzamido)-3-hydroxybenzoate |
| (V)409139-10-a | 1395964-06-3 | 2-(3,5-Dichlorophenyl)benzoxazole-6-carboxylic acid methyl ester |
| (VI)409139-10-a | 594839-88-0 | 2-(3,5-Dichlorophenyl)benzo[d]oxazole-6-carboxylic acid |
Frequently asked questions
What are the approved indications of Tafamidis Meglumine?
Approved indications include: 淀粉样多神经病, 转甲状腺素运载蛋白淀粉样变性, 淀粉样变.
When does the Tafamidis Meglumine patent expire?
No public expiry year is available for Tafamidis Meglumine yet; this page updates once verified.
How many synthesis routes are recorded for Tafamidis Meglumine?
6 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Tafamidis Meglumine intermediates?
2 intermediate CAS of Tafamidis Meglumine are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Tafamidis Meglumine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24